MedTrace Logo

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

NCT00595920 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2016-03-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting
  • Clinically Isolated Syndrome

Interventions

BIOLOGICAL

Tovaxin

2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.

Sponsors & Collaborators

  • Opexa Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Edward J Fox, MD, PhD · Central Texas Neurology Consultants

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00595920 on ClinicalTrials.gov